Global Urate-stimulating Excretion Agents Market Growth 2026-2032
The global Urate-stimulating Excretion Agents market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.
Urate-stimulating excretion agents are a class of medications designed to lower blood uric acid levels by enhancing its elimination from the body.They work by inhibiting the reabsorption of uric acid in the kidneys,which increases its excretion in the urine.These agents are used primarily in the treatment of chronic gout and hyperuricemia.
United States market for Urate-stimulating Excretion Agents is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Urate-stimulating Excretion Agents is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Urate-stimulating Excretion Agents is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Urate-stimulating Excretion Agents players cover Fuji Yakuhin, Lannett Company, Teva, Eisai, AstraZeneca, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Urate-stimulating Excretion Agents Industry Forecast” looks at past sales and reviews total world Urate-stimulating Excretion Agents sales in 2025, providing a comprehensive analysis by region and market sector of projected Urate-stimulating Excretion Agents sales for 2026 through 2032. With Urate-stimulating Excretion Agents sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Urate-stimulating Excretion Agents industry.
This Insight Report provides a comprehensive analysis of the global Urate-stimulating Excretion Agents landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Urate-stimulating Excretion Agents portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Urate-stimulating Excretion Agents market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Urate-stimulating Excretion Agents and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Urate-stimulating Excretion Agents.
This report presents a comprehensive overview, market shares, and growth opportunities of Urate-stimulating Excretion Agents market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Urate-stimulating Excretion Agents market?
What factors are driving Urate-stimulating Excretion Agents market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Urate-stimulating Excretion Agents market opportunities vary by end market size?
How does Urate-stimulating Excretion Agents break out by Type, by Application?
Urate-stimulating excretion agents are a class of medications designed to lower blood uric acid levels by enhancing its elimination from the body.They work by inhibiting the reabsorption of uric acid in the kidneys,which increases its excretion in the urine.These agents are used primarily in the treatment of chronic gout and hyperuricemia.
United States market for Urate-stimulating Excretion Agents is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
China market for Urate-stimulating Excretion Agents is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Europe market for Urate-stimulating Excretion Agents is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.
Global key Urate-stimulating Excretion Agents players cover Fuji Yakuhin, Lannett Company, Teva, Eisai, AstraZeneca, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.
LP Information, Inc. (LPI) ' newest research report, the “Urate-stimulating Excretion Agents Industry Forecast” looks at past sales and reviews total world Urate-stimulating Excretion Agents sales in 2025, providing a comprehensive analysis by region and market sector of projected Urate-stimulating Excretion Agents sales for 2026 through 2032. With Urate-stimulating Excretion Agents sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Urate-stimulating Excretion Agents industry.
This Insight Report provides a comprehensive analysis of the global Urate-stimulating Excretion Agents landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Urate-stimulating Excretion Agents portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Urate-stimulating Excretion Agents market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Urate-stimulating Excretion Agents and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Urate-stimulating Excretion Agents.
This report presents a comprehensive overview, market shares, and growth opportunities of Urate-stimulating Excretion Agents market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Benzbromarone
- Lesinurad
- Dotinurad
- Probenecid
- Other
- Hospitals and Clinics
- Retail Pharmacies
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Fuji Yakuhin
- Lannett Company
- Teva
- Eisai
- AstraZeneca
- Towa Pharmaceutical
- Excella
What is the 10-year outlook for the global Urate-stimulating Excretion Agents market?
What factors are driving Urate-stimulating Excretion Agents market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Urate-stimulating Excretion Agents market opportunities vary by end market size?
How does Urate-stimulating Excretion Agents break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Urate-stimulating Excretion Agents Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Urate-stimulating Excretion Agents by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Urate-stimulating Excretion Agents by Country/Region, 2021, 2025 & 2032
2.2 Urate-stimulating Excretion Agents Segment by Type
2.2.1 Benzbromarone
2.2.2 Lesinurad
2.2.3 Dotinurad
2.2.4 Probenecid
2.2.5 Other
2.2.6 Urate-stimulating Excretion Agents Sales by Type
2.2.6.1 Global Urate-stimulating Excretion Agents Sales Market Share by Type (2021-2026)
2.2.6.2 Global Urate-stimulating Excretion Agents Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Urate-stimulating Excretion Agents Sale Price by Type (2021-2026)
2.3 Urate-stimulating Excretion Agents Segment by Application
2.3.1 Hospitals and Clinics
2.3.2 Retail Pharmacies
2.3.3 Other
2.3.4 Urate-stimulating Excretion Agents Sales by Application
2.3.4.1 Global Urate-stimulating Excretion Agents Sale Market Share by Application (2021-2026)
2.3.4.2 Global Urate-stimulating Excretion Agents Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Urate-stimulating Excretion Agents Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Urate-stimulating Excretion Agents Breakdown Data by Company
3.1.1 Global Urate-stimulating Excretion Agents Annual Sales by Company (2021-2026)
3.1.2 Global Urate-stimulating Excretion Agents Sales Market Share by Company (2021-2026)
3.2 Global Urate-stimulating Excretion Agents Annual Revenue by Company (2021-2026)
3.2.1 Global Urate-stimulating Excretion Agents Revenue by Company (2021-2026)
3.2.2 Global Urate-stimulating Excretion Agents Revenue Market Share by Company (2021-2026)
3.3 Global Urate-stimulating Excretion Agents Sale Price by Company
3.4 Key Manufacturers Urate-stimulating Excretion Agents Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Urate-stimulating Excretion Agents Product Location Distribution
3.4.2 Players Urate-stimulating Excretion Agents Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR URATE-STIMULATING EXCRETION AGENTS BY GEOGRAPHIC REGION
4.1 World Historic Urate-stimulating Excretion Agents Market Size by Geographic Region (2021-2026)
4.1.1 Global Urate-stimulating Excretion Agents Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Urate-stimulating Excretion Agents Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Urate-stimulating Excretion Agents Market Size by Country/Region (2021-2026)
4.2.1 Global Urate-stimulating Excretion Agents Annual Sales by Country/Region (2021-2026)
4.2.2 Global Urate-stimulating Excretion Agents Annual Revenue by Country/Region (2021-2026)
4.3 Americas Urate-stimulating Excretion Agents Sales Growth
4.4 APAC Urate-stimulating Excretion Agents Sales Growth
4.5 Europe Urate-stimulating Excretion Agents Sales Growth
4.6 Middle East & Africa Urate-stimulating Excretion Agents Sales Growth
5 AMERICAS
5.1 Americas Urate-stimulating Excretion Agents Sales by Country
5.1.1 Americas Urate-stimulating Excretion Agents Sales by Country (2021-2026)
5.1.2 Americas Urate-stimulating Excretion Agents Revenue by Country (2021-2026)
5.2 Americas Urate-stimulating Excretion Agents Sales by Type (2021-2026)
5.3 Americas Urate-stimulating Excretion Agents Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Urate-stimulating Excretion Agents Sales by Region
6.1.1 APAC Urate-stimulating Excretion Agents Sales by Region (2021-2026)
6.1.2 APAC Urate-stimulating Excretion Agents Revenue by Region (2021-2026)
6.2 APAC Urate-stimulating Excretion Agents Sales by Type (2021-2026)
6.3 APAC Urate-stimulating Excretion Agents Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Urate-stimulating Excretion Agents by Country
7.1.1 Europe Urate-stimulating Excretion Agents Sales by Country (2021-2026)
7.1.2 Europe Urate-stimulating Excretion Agents Revenue by Country (2021-2026)
7.2 Europe Urate-stimulating Excretion Agents Sales by Type (2021-2026)
7.3 Europe Urate-stimulating Excretion Agents Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Urate-stimulating Excretion Agents by Country
8.1.1 Middle East & Africa Urate-stimulating Excretion Agents Sales by Country (2021-2026)
8.1.2 Middle East & Africa Urate-stimulating Excretion Agents Revenue by Country (2021-2026)
8.2 Middle East & Africa Urate-stimulating Excretion Agents Sales by Type (2021-2026)
8.3 Middle East & Africa Urate-stimulating Excretion Agents Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Urate-stimulating Excretion Agents
10.3 Manufacturing Process Analysis of Urate-stimulating Excretion Agents
10.4 Industry Chain Structure of Urate-stimulating Excretion Agents
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Urate-stimulating Excretion Agents Distributors
11.3 Urate-stimulating Excretion Agents Customer
12 WORLD FORECAST REVIEW FOR URATE-STIMULATING EXCRETION AGENTS BY GEOGRAPHIC REGION
12.1 Global Urate-stimulating Excretion Agents Market Size Forecast by Region
12.1.1 Global Urate-stimulating Excretion Agents Forecast by Region (2027-2032)
12.1.2 Global Urate-stimulating Excretion Agents Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Urate-stimulating Excretion Agents Forecast by Type (2027-2032)
12.7 Global Urate-stimulating Excretion Agents Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Fuji Yakuhin
13.1.1 Fuji Yakuhin Company Information
13.1.2 Fuji Yakuhin Urate-stimulating Excretion Agents Product Portfolios and Specifications
13.1.3 Fuji Yakuhin Urate-stimulating Excretion Agents Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Fuji Yakuhin Main Business Overview
13.1.5 Fuji Yakuhin Latest Developments
13.2 Lannett Company
13.2.1 Lannett Company Company Information
13.2.2 Lannett Company Urate-stimulating Excretion Agents Product Portfolios and Specifications
13.2.3 Lannett Company Urate-stimulating Excretion Agents Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Lannett Company Main Business Overview
13.2.5 Lannett Company Latest Developments
13.3 Teva
13.3.1 Teva Company Information
13.3.2 Teva Urate-stimulating Excretion Agents Product Portfolios and Specifications
13.3.3 Teva Urate-stimulating Excretion Agents Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Teva Main Business Overview
13.3.5 Teva Latest Developments
13.4 Eisai
13.4.1 Eisai Company Information
13.4.2 Eisai Urate-stimulating Excretion Agents Product Portfolios and Specifications
13.4.3 Eisai Urate-stimulating Excretion Agents Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Eisai Main Business Overview
13.4.5 Eisai Latest Developments
13.5 AstraZeneca
13.5.1 AstraZeneca Company Information
13.5.2 AstraZeneca Urate-stimulating Excretion Agents Product Portfolios and Specifications
13.5.3 AstraZeneca Urate-stimulating Excretion Agents Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 AstraZeneca Main Business Overview
13.5.5 AstraZeneca Latest Developments
13.6 Towa Pharmaceutical
13.6.1 Towa Pharmaceutical Company Information
13.6.2 Towa Pharmaceutical Urate-stimulating Excretion Agents Product Portfolios and Specifications
13.6.3 Towa Pharmaceutical Urate-stimulating Excretion Agents Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Towa Pharmaceutical Main Business Overview
13.6.5 Towa Pharmaceutical Latest Developments
13.7 Excella
13.7.1 Excella Company Information
13.7.2 Excella Urate-stimulating Excretion Agents Product Portfolios and Specifications
13.7.3 Excella Urate-stimulating Excretion Agents Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Excella Main Business Overview
13.7.5 Excella Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Urate-stimulating Excretion Agents Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Urate-stimulating Excretion Agents by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Urate-stimulating Excretion Agents by Country/Region, 2021, 2025 & 2032
2.2 Urate-stimulating Excretion Agents Segment by Type
2.2.1 Benzbromarone
2.2.2 Lesinurad
2.2.3 Dotinurad
2.2.4 Probenecid
2.2.5 Other
2.2.6 Urate-stimulating Excretion Agents Sales by Type
2.2.6.1 Global Urate-stimulating Excretion Agents Sales Market Share by Type (2021-2026)
2.2.6.2 Global Urate-stimulating Excretion Agents Revenue and Market Share by Type (2021-2026)
2.2.6.3 Global Urate-stimulating Excretion Agents Sale Price by Type (2021-2026)
2.3 Urate-stimulating Excretion Agents Segment by Application
2.3.1 Hospitals and Clinics
2.3.2 Retail Pharmacies
2.3.3 Other
2.3.4 Urate-stimulating Excretion Agents Sales by Application
2.3.4.1 Global Urate-stimulating Excretion Agents Sale Market Share by Application (2021-2026)
2.3.4.2 Global Urate-stimulating Excretion Agents Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global Urate-stimulating Excretion Agents Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Urate-stimulating Excretion Agents Breakdown Data by Company
3.1.1 Global Urate-stimulating Excretion Agents Annual Sales by Company (2021-2026)
3.1.2 Global Urate-stimulating Excretion Agents Sales Market Share by Company (2021-2026)
3.2 Global Urate-stimulating Excretion Agents Annual Revenue by Company (2021-2026)
3.2.1 Global Urate-stimulating Excretion Agents Revenue by Company (2021-2026)
3.2.2 Global Urate-stimulating Excretion Agents Revenue Market Share by Company (2021-2026)
3.3 Global Urate-stimulating Excretion Agents Sale Price by Company
3.4 Key Manufacturers Urate-stimulating Excretion Agents Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Urate-stimulating Excretion Agents Product Location Distribution
3.4.2 Players Urate-stimulating Excretion Agents Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR URATE-STIMULATING EXCRETION AGENTS BY GEOGRAPHIC REGION
4.1 World Historic Urate-stimulating Excretion Agents Market Size by Geographic Region (2021-2026)
4.1.1 Global Urate-stimulating Excretion Agents Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Urate-stimulating Excretion Agents Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Urate-stimulating Excretion Agents Market Size by Country/Region (2021-2026)
4.2.1 Global Urate-stimulating Excretion Agents Annual Sales by Country/Region (2021-2026)
4.2.2 Global Urate-stimulating Excretion Agents Annual Revenue by Country/Region (2021-2026)
4.3 Americas Urate-stimulating Excretion Agents Sales Growth
4.4 APAC Urate-stimulating Excretion Agents Sales Growth
4.5 Europe Urate-stimulating Excretion Agents Sales Growth
4.6 Middle East & Africa Urate-stimulating Excretion Agents Sales Growth
5 AMERICAS
5.1 Americas Urate-stimulating Excretion Agents Sales by Country
5.1.1 Americas Urate-stimulating Excretion Agents Sales by Country (2021-2026)
5.1.2 Americas Urate-stimulating Excretion Agents Revenue by Country (2021-2026)
5.2 Americas Urate-stimulating Excretion Agents Sales by Type (2021-2026)
5.3 Americas Urate-stimulating Excretion Agents Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Urate-stimulating Excretion Agents Sales by Region
6.1.1 APAC Urate-stimulating Excretion Agents Sales by Region (2021-2026)
6.1.2 APAC Urate-stimulating Excretion Agents Revenue by Region (2021-2026)
6.2 APAC Urate-stimulating Excretion Agents Sales by Type (2021-2026)
6.3 APAC Urate-stimulating Excretion Agents Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Urate-stimulating Excretion Agents by Country
7.1.1 Europe Urate-stimulating Excretion Agents Sales by Country (2021-2026)
7.1.2 Europe Urate-stimulating Excretion Agents Revenue by Country (2021-2026)
7.2 Europe Urate-stimulating Excretion Agents Sales by Type (2021-2026)
7.3 Europe Urate-stimulating Excretion Agents Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Urate-stimulating Excretion Agents by Country
8.1.1 Middle East & Africa Urate-stimulating Excretion Agents Sales by Country (2021-2026)
8.1.2 Middle East & Africa Urate-stimulating Excretion Agents Revenue by Country (2021-2026)
8.2 Middle East & Africa Urate-stimulating Excretion Agents Sales by Type (2021-2026)
8.3 Middle East & Africa Urate-stimulating Excretion Agents Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Urate-stimulating Excretion Agents
10.3 Manufacturing Process Analysis of Urate-stimulating Excretion Agents
10.4 Industry Chain Structure of Urate-stimulating Excretion Agents
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Urate-stimulating Excretion Agents Distributors
11.3 Urate-stimulating Excretion Agents Customer
12 WORLD FORECAST REVIEW FOR URATE-STIMULATING EXCRETION AGENTS BY GEOGRAPHIC REGION
12.1 Global Urate-stimulating Excretion Agents Market Size Forecast by Region
12.1.1 Global Urate-stimulating Excretion Agents Forecast by Region (2027-2032)
12.1.2 Global Urate-stimulating Excretion Agents Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Urate-stimulating Excretion Agents Forecast by Type (2027-2032)
12.7 Global Urate-stimulating Excretion Agents Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Fuji Yakuhin
13.1.1 Fuji Yakuhin Company Information
13.1.2 Fuji Yakuhin Urate-stimulating Excretion Agents Product Portfolios and Specifications
13.1.3 Fuji Yakuhin Urate-stimulating Excretion Agents Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Fuji Yakuhin Main Business Overview
13.1.5 Fuji Yakuhin Latest Developments
13.2 Lannett Company
13.2.1 Lannett Company Company Information
13.2.2 Lannett Company Urate-stimulating Excretion Agents Product Portfolios and Specifications
13.2.3 Lannett Company Urate-stimulating Excretion Agents Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Lannett Company Main Business Overview
13.2.5 Lannett Company Latest Developments
13.3 Teva
13.3.1 Teva Company Information
13.3.2 Teva Urate-stimulating Excretion Agents Product Portfolios and Specifications
13.3.3 Teva Urate-stimulating Excretion Agents Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Teva Main Business Overview
13.3.5 Teva Latest Developments
13.4 Eisai
13.4.1 Eisai Company Information
13.4.2 Eisai Urate-stimulating Excretion Agents Product Portfolios and Specifications
13.4.3 Eisai Urate-stimulating Excretion Agents Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Eisai Main Business Overview
13.4.5 Eisai Latest Developments
13.5 AstraZeneca
13.5.1 AstraZeneca Company Information
13.5.2 AstraZeneca Urate-stimulating Excretion Agents Product Portfolios and Specifications
13.5.3 AstraZeneca Urate-stimulating Excretion Agents Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 AstraZeneca Main Business Overview
13.5.5 AstraZeneca Latest Developments
13.6 Towa Pharmaceutical
13.6.1 Towa Pharmaceutical Company Information
13.6.2 Towa Pharmaceutical Urate-stimulating Excretion Agents Product Portfolios and Specifications
13.6.3 Towa Pharmaceutical Urate-stimulating Excretion Agents Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Towa Pharmaceutical Main Business Overview
13.6.5 Towa Pharmaceutical Latest Developments
13.7 Excella
13.7.1 Excella Company Information
13.7.2 Excella Urate-stimulating Excretion Agents Product Portfolios and Specifications
13.7.3 Excella Urate-stimulating Excretion Agents Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Excella Main Business Overview
13.7.5 Excella Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Urate-stimulating Excretion Agents Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Urate-stimulating Excretion Agents Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Benzbromarone
Table 4. Major Players of Lesinurad
Table 5. Major Players of Dotinurad
Table 6. Major Players of Probenecid
Table 7. Major Players of Other
Table 8. Global Urate-stimulating Excretion Agents Sales by Type (2021-2026) & (K Units)
Table 9. Global Urate-stimulating Excretion Agents Sales Market Share by Type (2021-2026)
Table 10. Global Urate-stimulating Excretion Agents Revenue by Type (2021-2026) & ($ million)
Table 11. Global Urate-stimulating Excretion Agents Revenue Market Share by Type (2021-2026)
Table 12. Global Urate-stimulating Excretion Agents Sale Price by Type (2021-2026) & (US$/Unit)
Table 13. Global Urate-stimulating Excretion Agents Sale by Application (2021-2026) & (K Units)
Table 14. Global Urate-stimulating Excretion Agents Sale Market Share by Application (2021-2026)
Table 15. Global Urate-stimulating Excretion Agents Revenue by Application (2021-2026) & ($ million)
Table 16. Global Urate-stimulating Excretion Agents Revenue Market Share by Application (2021-2026)
Table 17. Global Urate-stimulating Excretion Agents Sale Price by Application (2021-2026) & (US$/Unit)
Table 18. Global Urate-stimulating Excretion Agents Sales by Company (2021-2026) & (K Units)
Table 19. Global Urate-stimulating Excretion Agents Sales Market Share by Company (2021-2026)
Table 20. Global Urate-stimulating Excretion Agents Revenue by Company (2021-2026) & ($ millions)
Table 21. Global Urate-stimulating Excretion Agents Revenue Market Share by Company (2021-2026)
Table 22. Global Urate-stimulating Excretion Agents Sale Price by Company (2021-2026) & (US$/Unit)
Table 23. Key Manufacturers Urate-stimulating Excretion Agents Producing Area Distribution and Sales Area
Table 24. Players Urate-stimulating Excretion Agents Products Offered
Table 25. Urate-stimulating Excretion Agents Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Urate-stimulating Excretion Agents Sales by Geographic Region (2021-2026) & (K Units)
Table 29. Global Urate-stimulating Excretion Agents Sales Market Share Geographic Region (2021-2026)
Table 30. Global Urate-stimulating Excretion Agents Revenue by Geographic Region (2021-2026) & ($ millions)
Table 31. Global Urate-stimulating Excretion Agents Revenue Market Share by Geographic Region (2021-2026)
Table 32. Global Urate-stimulating Excretion Agents Sales by Country/Region (2021-2026) & (K Units)
Table 33. Global Urate-stimulating Excretion Agents Sales Market Share by Country/Region (2021-2026)
Table 34. Global Urate-stimulating Excretion Agents Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global Urate-stimulating Excretion Agents Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas Urate-stimulating Excretion Agents Sales by Country (2021-2026) & (K Units)
Table 37. Americas Urate-stimulating Excretion Agents Sales Market Share by Country (2021-2026)
Table 38. Americas Urate-stimulating Excretion Agents Revenue by Country (2021-2026) & ($ millions)
Table 39. Americas Urate-stimulating Excretion Agents Sales by Type (2021-2026) & (K Units)
Table 40. Americas Urate-stimulating Excretion Agents Sales by Application (2021-2026) & (K Units)
Table 41. APAC Urate-stimulating Excretion Agents Sales by Region (2021-2026) & (K Units)
Table 42. APAC Urate-stimulating Excretion Agents Sales Market Share by Region (2021-2026)
Table 43. APAC Urate-stimulating Excretion Agents Revenue by Region (2021-2026) & ($ millions)
Table 44. APAC Urate-stimulating Excretion Agents Sales by Type (2021-2026) & (K Units)
Table 45. APAC Urate-stimulating Excretion Agents Sales by Application (2021-2026) & (K Units)
Table 46. Europe Urate-stimulating Excretion Agents Sales by Country (2021-2026) & (K Units)
Table 47. Europe Urate-stimulating Excretion Agents Revenue by Country (2021-2026) & ($ millions)
Table 48. Europe Urate-stimulating Excretion Agents Sales by Type (2021-2026) & (K Units)
Table 49. Europe Urate-stimulating Excretion Agents Sales by Application (2021-2026) & (K Units)
Table 50. Middle East & Africa Urate-stimulating Excretion Agents Sales by Country (2021-2026) & (K Units)
Table 51. Middle East & Africa Urate-stimulating Excretion Agents Revenue Market Share by Country (2021-2026)
Table 52. Middle East & Africa Urate-stimulating Excretion Agents Sales by Type (2021-2026) & (K Units)
Table 53. Middle East & Africa Urate-stimulating Excretion Agents Sales by Application (2021-2026) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities of Urate-stimulating Excretion Agents
Table 55. Key Market Challenges & Risks of Urate-stimulating Excretion Agents
Table 56. Key Industry Trends of Urate-stimulating Excretion Agents
Table 57. Urate-stimulating Excretion Agents Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Urate-stimulating Excretion Agents Distributors List
Table 60. Urate-stimulating Excretion Agents Customer List
Table 61. Global Urate-stimulating Excretion Agents Sales Forecast by Region (2027-2032) & (K Units)
Table 62. Global Urate-stimulating Excretion Agents Revenue Forecast by Region (2027-2032) & ($ millions)
Table 63. Americas Urate-stimulating Excretion Agents Sales Forecast by Country (2027-2032) & (K Units)
Table 64. Americas Urate-stimulating Excretion Agents Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 65. APAC Urate-stimulating Excretion Agents Sales Forecast by Region (2027-2032) & (K Units)
Table 66. APAC Urate-stimulating Excretion Agents Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 67. Europe Urate-stimulating Excretion Agents Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Europe Urate-stimulating Excretion Agents Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Middle East & Africa Urate-stimulating Excretion Agents Sales Forecast by Country (2027-2032) & (K Units)
Table 70. Middle East & Africa Urate-stimulating Excretion Agents Revenue Forecast by Country (2027-2032) & ($ millions)
Table 71. Global Urate-stimulating Excretion Agents Sales Forecast by Type (2027-2032) & (K Units)
Table 72. Global Urate-stimulating Excretion Agents Revenue Forecast by Type (2027-2032) & ($ millions)
Table 73. Global Urate-stimulating Excretion Agents Sales Forecast by Application (2027-2032) & (K Units)
Table 74. Global Urate-stimulating Excretion Agents Revenue Forecast by Application (2027-2032) & ($ millions)
Table 75. Fuji Yakuhin Basic Information, Urate-stimulating Excretion Agents Manufacturing Base, Sales Area and Its Competitors
Table 76. Fuji Yakuhin Urate-stimulating Excretion Agents Product Portfolios and Specifications
Table 77. Fuji Yakuhin Urate-stimulating Excretion Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 78. Fuji Yakuhin Main Business
Table 79. Fuji Yakuhin Latest Developments
Table 80. Lannett Company Basic Information, Urate-stimulating Excretion Agents Manufacturing Base, Sales Area and Its Competitors
Table 81. Lannett Company Urate-stimulating Excretion Agents Product Portfolios and Specifications
Table 82. Lannett Company Urate-stimulating Excretion Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 83. Lannett Company Main Business
Table 84. Lannett Company Latest Developments
Table 85. Teva Basic Information, Urate-stimulating Excretion Agents Manufacturing Base, Sales Area and Its Competitors
Table 86. Teva Urate-stimulating Excretion Agents Product Portfolios and Specifications
Table 87. Teva Urate-stimulating Excretion Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 88. Teva Main Business
Table 89. Teva Latest Developments
Table 90. Eisai Basic Information, Urate-stimulating Excretion Agents Manufacturing Base, Sales Area and Its Competitors
Table 91. Eisai Urate-stimulating Excretion Agents Product Portfolios and Specifications
Table 92. Eisai Urate-stimulating Excretion Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 93. Eisai Main Business
Table 94. Eisai Latest Developments
Table 95. AstraZeneca Basic Information, Urate-stimulating Excretion Agents Manufacturing Base, Sales Area and Its Competitors
Table 96. AstraZeneca Urate-stimulating Excretion Agents Product Portfolios and Specifications
Table 97. AstraZeneca Urate-stimulating Excretion Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. AstraZeneca Main Business
Table 99. AstraZeneca Latest Developments
Table 100. Towa Pharmaceutical Basic Information, Urate-stimulating Excretion Agents Manufacturing Base, Sales Area and Its Competitors
Table 101. Towa Pharmaceutical Urate-stimulating Excretion Agents Product Portfolios and Specifications
Table 102. Towa Pharmaceutical Urate-stimulating Excretion Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 103. Towa Pharmaceutical Main Business
Table 104. Towa Pharmaceutical Latest Developments
Table 105. Excella Basic Information, Urate-stimulating Excretion Agents Manufacturing Base, Sales Area and Its Competitors
Table 106. Excella Urate-stimulating Excretion Agents Product Portfolios and Specifications
Table 107. Excella Urate-stimulating Excretion Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 108. Excella Main Business
Table 109. Excella Latest Developments
Table 1. Urate-stimulating Excretion Agents Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Urate-stimulating Excretion Agents Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Benzbromarone
Table 4. Major Players of Lesinurad
Table 5. Major Players of Dotinurad
Table 6. Major Players of Probenecid
Table 7. Major Players of Other
Table 8. Global Urate-stimulating Excretion Agents Sales by Type (2021-2026) & (K Units)
Table 9. Global Urate-stimulating Excretion Agents Sales Market Share by Type (2021-2026)
Table 10. Global Urate-stimulating Excretion Agents Revenue by Type (2021-2026) & ($ million)
Table 11. Global Urate-stimulating Excretion Agents Revenue Market Share by Type (2021-2026)
Table 12. Global Urate-stimulating Excretion Agents Sale Price by Type (2021-2026) & (US$/Unit)
Table 13. Global Urate-stimulating Excretion Agents Sale by Application (2021-2026) & (K Units)
Table 14. Global Urate-stimulating Excretion Agents Sale Market Share by Application (2021-2026)
Table 15. Global Urate-stimulating Excretion Agents Revenue by Application (2021-2026) & ($ million)
Table 16. Global Urate-stimulating Excretion Agents Revenue Market Share by Application (2021-2026)
Table 17. Global Urate-stimulating Excretion Agents Sale Price by Application (2021-2026) & (US$/Unit)
Table 18. Global Urate-stimulating Excretion Agents Sales by Company (2021-2026) & (K Units)
Table 19. Global Urate-stimulating Excretion Agents Sales Market Share by Company (2021-2026)
Table 20. Global Urate-stimulating Excretion Agents Revenue by Company (2021-2026) & ($ millions)
Table 21. Global Urate-stimulating Excretion Agents Revenue Market Share by Company (2021-2026)
Table 22. Global Urate-stimulating Excretion Agents Sale Price by Company (2021-2026) & (US$/Unit)
Table 23. Key Manufacturers Urate-stimulating Excretion Agents Producing Area Distribution and Sales Area
Table 24. Players Urate-stimulating Excretion Agents Products Offered
Table 25. Urate-stimulating Excretion Agents Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 26. New Products and Potential Entrants
Table 27. Market M&A Activity & Strategy
Table 28. Global Urate-stimulating Excretion Agents Sales by Geographic Region (2021-2026) & (K Units)
Table 29. Global Urate-stimulating Excretion Agents Sales Market Share Geographic Region (2021-2026)
Table 30. Global Urate-stimulating Excretion Agents Revenue by Geographic Region (2021-2026) & ($ millions)
Table 31. Global Urate-stimulating Excretion Agents Revenue Market Share by Geographic Region (2021-2026)
Table 32. Global Urate-stimulating Excretion Agents Sales by Country/Region (2021-2026) & (K Units)
Table 33. Global Urate-stimulating Excretion Agents Sales Market Share by Country/Region (2021-2026)
Table 34. Global Urate-stimulating Excretion Agents Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global Urate-stimulating Excretion Agents Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas Urate-stimulating Excretion Agents Sales by Country (2021-2026) & (K Units)
Table 37. Americas Urate-stimulating Excretion Agents Sales Market Share by Country (2021-2026)
Table 38. Americas Urate-stimulating Excretion Agents Revenue by Country (2021-2026) & ($ millions)
Table 39. Americas Urate-stimulating Excretion Agents Sales by Type (2021-2026) & (K Units)
Table 40. Americas Urate-stimulating Excretion Agents Sales by Application (2021-2026) & (K Units)
Table 41. APAC Urate-stimulating Excretion Agents Sales by Region (2021-2026) & (K Units)
Table 42. APAC Urate-stimulating Excretion Agents Sales Market Share by Region (2021-2026)
Table 43. APAC Urate-stimulating Excretion Agents Revenue by Region (2021-2026) & ($ millions)
Table 44. APAC Urate-stimulating Excretion Agents Sales by Type (2021-2026) & (K Units)
Table 45. APAC Urate-stimulating Excretion Agents Sales by Application (2021-2026) & (K Units)
Table 46. Europe Urate-stimulating Excretion Agents Sales by Country (2021-2026) & (K Units)
Table 47. Europe Urate-stimulating Excretion Agents Revenue by Country (2021-2026) & ($ millions)
Table 48. Europe Urate-stimulating Excretion Agents Sales by Type (2021-2026) & (K Units)
Table 49. Europe Urate-stimulating Excretion Agents Sales by Application (2021-2026) & (K Units)
Table 50. Middle East & Africa Urate-stimulating Excretion Agents Sales by Country (2021-2026) & (K Units)
Table 51. Middle East & Africa Urate-stimulating Excretion Agents Revenue Market Share by Country (2021-2026)
Table 52. Middle East & Africa Urate-stimulating Excretion Agents Sales by Type (2021-2026) & (K Units)
Table 53. Middle East & Africa Urate-stimulating Excretion Agents Sales by Application (2021-2026) & (K Units)
Table 54. Key Market Drivers & Growth Opportunities of Urate-stimulating Excretion Agents
Table 55. Key Market Challenges & Risks of Urate-stimulating Excretion Agents
Table 56. Key Industry Trends of Urate-stimulating Excretion Agents
Table 57. Urate-stimulating Excretion Agents Raw Material
Table 58. Key Suppliers of Raw Materials
Table 59. Urate-stimulating Excretion Agents Distributors List
Table 60. Urate-stimulating Excretion Agents Customer List
Table 61. Global Urate-stimulating Excretion Agents Sales Forecast by Region (2027-2032) & (K Units)
Table 62. Global Urate-stimulating Excretion Agents Revenue Forecast by Region (2027-2032) & ($ millions)
Table 63. Americas Urate-stimulating Excretion Agents Sales Forecast by Country (2027-2032) & (K Units)
Table 64. Americas Urate-stimulating Excretion Agents Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 65. APAC Urate-stimulating Excretion Agents Sales Forecast by Region (2027-2032) & (K Units)
Table 66. APAC Urate-stimulating Excretion Agents Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 67. Europe Urate-stimulating Excretion Agents Sales Forecast by Country (2027-2032) & (K Units)
Table 68. Europe Urate-stimulating Excretion Agents Revenue Forecast by Country (2027-2032) & ($ millions)
Table 69. Middle East & Africa Urate-stimulating Excretion Agents Sales Forecast by Country (2027-2032) & (K Units)
Table 70. Middle East & Africa Urate-stimulating Excretion Agents Revenue Forecast by Country (2027-2032) & ($ millions)
Table 71. Global Urate-stimulating Excretion Agents Sales Forecast by Type (2027-2032) & (K Units)
Table 72. Global Urate-stimulating Excretion Agents Revenue Forecast by Type (2027-2032) & ($ millions)
Table 73. Global Urate-stimulating Excretion Agents Sales Forecast by Application (2027-2032) & (K Units)
Table 74. Global Urate-stimulating Excretion Agents Revenue Forecast by Application (2027-2032) & ($ millions)
Table 75. Fuji Yakuhin Basic Information, Urate-stimulating Excretion Agents Manufacturing Base, Sales Area and Its Competitors
Table 76. Fuji Yakuhin Urate-stimulating Excretion Agents Product Portfolios and Specifications
Table 77. Fuji Yakuhin Urate-stimulating Excretion Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 78. Fuji Yakuhin Main Business
Table 79. Fuji Yakuhin Latest Developments
Table 80. Lannett Company Basic Information, Urate-stimulating Excretion Agents Manufacturing Base, Sales Area and Its Competitors
Table 81. Lannett Company Urate-stimulating Excretion Agents Product Portfolios and Specifications
Table 82. Lannett Company Urate-stimulating Excretion Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 83. Lannett Company Main Business
Table 84. Lannett Company Latest Developments
Table 85. Teva Basic Information, Urate-stimulating Excretion Agents Manufacturing Base, Sales Area and Its Competitors
Table 86. Teva Urate-stimulating Excretion Agents Product Portfolios and Specifications
Table 87. Teva Urate-stimulating Excretion Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 88. Teva Main Business
Table 89. Teva Latest Developments
Table 90. Eisai Basic Information, Urate-stimulating Excretion Agents Manufacturing Base, Sales Area and Its Competitors
Table 91. Eisai Urate-stimulating Excretion Agents Product Portfolios and Specifications
Table 92. Eisai Urate-stimulating Excretion Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 93. Eisai Main Business
Table 94. Eisai Latest Developments
Table 95. AstraZeneca Basic Information, Urate-stimulating Excretion Agents Manufacturing Base, Sales Area and Its Competitors
Table 96. AstraZeneca Urate-stimulating Excretion Agents Product Portfolios and Specifications
Table 97. AstraZeneca Urate-stimulating Excretion Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. AstraZeneca Main Business
Table 99. AstraZeneca Latest Developments
Table 100. Towa Pharmaceutical Basic Information, Urate-stimulating Excretion Agents Manufacturing Base, Sales Area and Its Competitors
Table 101. Towa Pharmaceutical Urate-stimulating Excretion Agents Product Portfolios and Specifications
Table 102. Towa Pharmaceutical Urate-stimulating Excretion Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 103. Towa Pharmaceutical Main Business
Table 104. Towa Pharmaceutical Latest Developments
Table 105. Excella Basic Information, Urate-stimulating Excretion Agents Manufacturing Base, Sales Area and Its Competitors
Table 106. Excella Urate-stimulating Excretion Agents Product Portfolios and Specifications
Table 107. Excella Urate-stimulating Excretion Agents Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 108. Excella Main Business
Table 109. Excella Latest Developments
LIST OF FIGURES
Figure 1. Picture of Urate-stimulating Excretion Agents
Figure 2. Urate-stimulating Excretion Agents Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Urate-stimulating Excretion Agents Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Urate-stimulating Excretion Agents Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Urate-stimulating Excretion Agents Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Urate-stimulating Excretion Agents Sales Market Share by Country/Region (2025)
Figure 10. Urate-stimulating Excretion Agents Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Benzbromarone
Figure 12. Product Picture of Lesinurad
Figure 13. Product Picture of Dotinurad
Figure 14. Product Picture of Probenecid
Figure 15. Product Picture of Other
Figure 16. Global Urate-stimulating Excretion Agents Sales Market Share by Type in 2026
Figure 17. Global Urate-stimulating Excretion Agents Revenue Market Share by Type (2021-2026)
Figure 18. Urate-stimulating Excretion Agents Consumed in Hospitals and Clinics
Figure 19. Global Urate-stimulating Excretion Agents Market: Hospitals and Clinics (2021-2026) & (K Units)
Figure 20. Urate-stimulating Excretion Agents Consumed in Retail Pharmacies
Figure 21. Global Urate-stimulating Excretion Agents Market: Retail Pharmacies (2021-2026) & (K Units)
Figure 22. Urate-stimulating Excretion Agents Consumed in Other
Figure 23. Global Urate-stimulating Excretion Agents Market: Other (2021-2026) & (K Units)
Figure 24. Global Urate-stimulating Excretion Agents Sale Market Share by Application (2025)
Figure 25. Global Urate-stimulating Excretion Agents Revenue Market Share by Application in 2026
Figure 26. Urate-stimulating Excretion Agents Sales by Company in 2026 (K Units)
Figure 27. Global Urate-stimulating Excretion Agents Sales Market Share by Company in 2026
Figure 28. Urate-stimulating Excretion Agents Revenue by Company in 2026 ($ millions)
Figure 29. Global Urate-stimulating Excretion Agents Revenue Market Share by Company in 2026
Figure 30. Global Urate-stimulating Excretion Agents Sales Market Share by Geographic Region (2021-2026)
Figure 31. Global Urate-stimulating Excretion Agents Revenue Market Share by Geographic Region in 2026
Figure 32. Americas Urate-stimulating Excretion Agents Sales 2021-2026 (K Units)
Figure 33. Americas Urate-stimulating Excretion Agents Revenue 2021-2026 ($ millions)
Figure 34. APAC Urate-stimulating Excretion Agents Sales 2021-2026 (K Units)
Figure 35. APAC Urate-stimulating Excretion Agents Revenue 2021-2026 ($ millions)
Figure 36. Europe Urate-stimulating Excretion Agents Sales 2021-2026 (K Units)
Figure 37. Europe Urate-stimulating Excretion Agents Revenue 2021-2026 ($ millions)
Figure 38. Middle East & Africa Urate-stimulating Excretion Agents Sales 2021-2026 (K Units)
Figure 39. Middle East & Africa Urate-stimulating Excretion Agents Revenue 2021-2026 ($ millions)
Figure 40. Americas Urate-stimulating Excretion Agents Sales Market Share by Country in 2026
Figure 41. Americas Urate-stimulating Excretion Agents Revenue Market Share by Country (2021-2026)
Figure 42. Americas Urate-stimulating Excretion Agents Sales Market Share by Type (2021-2026)
Figure 43. Americas Urate-stimulating Excretion Agents Sales Market Share by Application (2021-2026)
Figure 44. United States Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 45. Canada Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 46. Mexico Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 47. Brazil Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 48. APAC Urate-stimulating Excretion Agents Sales Market Share by Region in 2026
Figure 49. APAC Urate-stimulating Excretion Agents Revenue Market Share by Region (2021-2026)
Figure 50. APAC Urate-stimulating Excretion Agents Sales Market Share by Type (2021-2026)
Figure 51. APAC Urate-stimulating Excretion Agents Sales Market Share by Application (2021-2026)
Figure 52. China Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 53. Japan Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 54. South Korea Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 55. Southeast Asia Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 56. India Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 57. Australia Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 58. China Taiwan Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 59. Europe Urate-stimulating Excretion Agents Sales Market Share by Country in 2026
Figure 60. Europe Urate-stimulating Excretion Agents Revenue Market Share by Country (2021-2026)
Figure 61. Europe Urate-stimulating Excretion Agents Sales Market Share by Type (2021-2026)
Figure 62. Europe Urate-stimulating Excretion Agents Sales Market Share by Application (2021-2026)
Figure 63. Germany Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 64. France Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 65. UK Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 66. Italy Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 67. Russia Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 68. Middle East & Africa Urate-stimulating Excretion Agents Sales Market Share by Country (2021-2026)
Figure 69. Middle East & Africa Urate-stimulating Excretion Agents Sales Market Share by Type (2021-2026)
Figure 70. Middle East & Africa Urate-stimulating Excretion Agents Sales Market Share by Application (2021-2026)
Figure 71. Egypt Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 72. South Africa Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 73. Israel Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 74. Turkey Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 75. GCC Countries Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Urate-stimulating Excretion Agents in 2026
Figure 77. Manufacturing Process Analysis of Urate-stimulating Excretion Agents
Figure 78. Industry Chain Structure of Urate-stimulating Excretion Agents
Figure 79. Channels of Distribution
Figure 80. Global Urate-stimulating Excretion Agents Sales Market Forecast by Region (2027-2032)
Figure 81. Global Urate-stimulating Excretion Agents Revenue Market Share Forecast by Region (2027-2032)
Figure 82. Global Urate-stimulating Excretion Agents Sales Market Share Forecast by Type (2027-2032)
Figure 83. Global Urate-stimulating Excretion Agents Revenue Market Share Forecast by Type (2027-2032)
Figure 84. Global Urate-stimulating Excretion Agents Sales Market Share Forecast by Application (2027-2032)
Figure 85. Global Urate-stimulating Excretion Agents Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Urate-stimulating Excretion Agents
Figure 2. Urate-stimulating Excretion Agents Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Urate-stimulating Excretion Agents Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Urate-stimulating Excretion Agents Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Urate-stimulating Excretion Agents Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Urate-stimulating Excretion Agents Sales Market Share by Country/Region (2025)
Figure 10. Urate-stimulating Excretion Agents Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Benzbromarone
Figure 12. Product Picture of Lesinurad
Figure 13. Product Picture of Dotinurad
Figure 14. Product Picture of Probenecid
Figure 15. Product Picture of Other
Figure 16. Global Urate-stimulating Excretion Agents Sales Market Share by Type in 2026
Figure 17. Global Urate-stimulating Excretion Agents Revenue Market Share by Type (2021-2026)
Figure 18. Urate-stimulating Excretion Agents Consumed in Hospitals and Clinics
Figure 19. Global Urate-stimulating Excretion Agents Market: Hospitals and Clinics (2021-2026) & (K Units)
Figure 20. Urate-stimulating Excretion Agents Consumed in Retail Pharmacies
Figure 21. Global Urate-stimulating Excretion Agents Market: Retail Pharmacies (2021-2026) & (K Units)
Figure 22. Urate-stimulating Excretion Agents Consumed in Other
Figure 23. Global Urate-stimulating Excretion Agents Market: Other (2021-2026) & (K Units)
Figure 24. Global Urate-stimulating Excretion Agents Sale Market Share by Application (2025)
Figure 25. Global Urate-stimulating Excretion Agents Revenue Market Share by Application in 2026
Figure 26. Urate-stimulating Excretion Agents Sales by Company in 2026 (K Units)
Figure 27. Global Urate-stimulating Excretion Agents Sales Market Share by Company in 2026
Figure 28. Urate-stimulating Excretion Agents Revenue by Company in 2026 ($ millions)
Figure 29. Global Urate-stimulating Excretion Agents Revenue Market Share by Company in 2026
Figure 30. Global Urate-stimulating Excretion Agents Sales Market Share by Geographic Region (2021-2026)
Figure 31. Global Urate-stimulating Excretion Agents Revenue Market Share by Geographic Region in 2026
Figure 32. Americas Urate-stimulating Excretion Agents Sales 2021-2026 (K Units)
Figure 33. Americas Urate-stimulating Excretion Agents Revenue 2021-2026 ($ millions)
Figure 34. APAC Urate-stimulating Excretion Agents Sales 2021-2026 (K Units)
Figure 35. APAC Urate-stimulating Excretion Agents Revenue 2021-2026 ($ millions)
Figure 36. Europe Urate-stimulating Excretion Agents Sales 2021-2026 (K Units)
Figure 37. Europe Urate-stimulating Excretion Agents Revenue 2021-2026 ($ millions)
Figure 38. Middle East & Africa Urate-stimulating Excretion Agents Sales 2021-2026 (K Units)
Figure 39. Middle East & Africa Urate-stimulating Excretion Agents Revenue 2021-2026 ($ millions)
Figure 40. Americas Urate-stimulating Excretion Agents Sales Market Share by Country in 2026
Figure 41. Americas Urate-stimulating Excretion Agents Revenue Market Share by Country (2021-2026)
Figure 42. Americas Urate-stimulating Excretion Agents Sales Market Share by Type (2021-2026)
Figure 43. Americas Urate-stimulating Excretion Agents Sales Market Share by Application (2021-2026)
Figure 44. United States Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 45. Canada Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 46. Mexico Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 47. Brazil Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 48. APAC Urate-stimulating Excretion Agents Sales Market Share by Region in 2026
Figure 49. APAC Urate-stimulating Excretion Agents Revenue Market Share by Region (2021-2026)
Figure 50. APAC Urate-stimulating Excretion Agents Sales Market Share by Type (2021-2026)
Figure 51. APAC Urate-stimulating Excretion Agents Sales Market Share by Application (2021-2026)
Figure 52. China Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 53. Japan Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 54. South Korea Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 55. Southeast Asia Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 56. India Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 57. Australia Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 58. China Taiwan Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 59. Europe Urate-stimulating Excretion Agents Sales Market Share by Country in 2026
Figure 60. Europe Urate-stimulating Excretion Agents Revenue Market Share by Country (2021-2026)
Figure 61. Europe Urate-stimulating Excretion Agents Sales Market Share by Type (2021-2026)
Figure 62. Europe Urate-stimulating Excretion Agents Sales Market Share by Application (2021-2026)
Figure 63. Germany Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 64. France Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 65. UK Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 66. Italy Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 67. Russia Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 68. Middle East & Africa Urate-stimulating Excretion Agents Sales Market Share by Country (2021-2026)
Figure 69. Middle East & Africa Urate-stimulating Excretion Agents Sales Market Share by Type (2021-2026)
Figure 70. Middle East & Africa Urate-stimulating Excretion Agents Sales Market Share by Application (2021-2026)
Figure 71. Egypt Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 72. South Africa Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 73. Israel Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 74. Turkey Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 75. GCC Countries Urate-stimulating Excretion Agents Revenue Growth 2021-2026 ($ millions)
Figure 76. Manufacturing Cost Structure Analysis of Urate-stimulating Excretion Agents in 2026
Figure 77. Manufacturing Process Analysis of Urate-stimulating Excretion Agents
Figure 78. Industry Chain Structure of Urate-stimulating Excretion Agents
Figure 79. Channels of Distribution
Figure 80. Global Urate-stimulating Excretion Agents Sales Market Forecast by Region (2027-2032)
Figure 81. Global Urate-stimulating Excretion Agents Revenue Market Share Forecast by Region (2027-2032)
Figure 82. Global Urate-stimulating Excretion Agents Sales Market Share Forecast by Type (2027-2032)
Figure 83. Global Urate-stimulating Excretion Agents Revenue Market Share Forecast by Type (2027-2032)
Figure 84. Global Urate-stimulating Excretion Agents Sales Market Share Forecast by Application (2027-2032)
Figure 85. Global Urate-stimulating Excretion Agents Revenue Market Share Forecast by Application (2027-2032)
